Journal of Virology · 2019 · 44 citations · 44 references
Life SciencesImmunologyInfectious DiseasesImmunizationVaccine ImmunologyVaccinologyClinical Vaccine TrialsHumoral ImmunityImmune Response To VaccinationImmunization SchedulesPrime-boost ImmunizationVaccinationAntibody Binding KineticsBinding Antibody ResponsesDurability Of ImmunityEbola VaccinesImmune Response DurabilityPrime-boost Sequence EffectsSerologic Response To Booster VaccinationVaccine Response Modeling
With no available licensed vaccines or therapies, the West African Ebola virus disease epidemic of 2014 to 2016 caused 11,310 deaths. Following this outbreak, the development of vaccines has been accelerated. Combining different vector-based vaccines as heterologous regimens could induce a durable immune response, assessed through antibody concentrations. Based on data from phase 1 trials in East Africa and Europe, the dynamics of the humoral immune response from 7 days after the boost immunization onwards were modeled to estimate the durability of the response and understand its variability. Antibody production is maintained by a population of long-lived cells. Estimation suggests that half of these cells can persist for at least 5 years in humans. Differences in prime-boost vaccine regimens affect only the short-term immune response. Geographical differences in long-lived cell dynamics were inferred, with higher long-term antibody concentrations induced in European participants.
44
Humoral Immunity Due to Long-Lived Plasma Cells
Mark K. Slifka, Rustom Antia, Jason K. Whitmire et al. · Immunity · 1998 · 1.3K citations · Full text
Distinct short‐lived and long‐lived antibody‐producing cell populations
Faith Ho, J. Lortan, Ian C. M. MacLennan et al. · European Journal of Immunology · 1986 · 271 citations